Francesco Pichi1,2, Piergorgio Neri1,2, Aniruddha Agarwal3, Alessandro Invernizzi4,5, Netan Choudhry6, Radgonde Amer7, Andrea Lembo8, Paolo Nucci8, Ian Thompson9, H Nida Sen9, Carol L Shields10. 1. Cleveland Clinic Abu Dhabi, Eye Institute, Abu Dhabi, United Arab Emirates. 2. Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio. 3. Advanced Eye Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India. 4. Eye Clinic, Department of Biomedical and Clinical Science 'Luigi Sacco', Luigi Sacco Hospital, University of Milan, Milan, Italy. 5. Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia. 6. Vitreous Retina Macula Specialists of Toronto, Toronto, Canada. 7. Hadassah Medical Center, Jerusalem, Israel. 8. San Giuseppe Hospital, University Eye Clinic, Milan, Italy. 9. National Eye Institute, National Institute of Health, Bethesda, Maryland; and. 10. Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Abstract
PURPOSE: To describe patients with intermediate uveitis complicated by vasoproliferative tumors (VPTs). METHODS: Data were collected at seven Uveitis/Ocular Oncology centers on demographic, ophthalmic findings at baseline and at follow-up, and on imaging. The therapeutic intervention, final visual acuity, and duration of follow-up were recorded. RESULTS: A total of 36 eyes from 34 patients (12 men, 22 women; mean age 35.3 ± 14.2 years) were included in this study. Visual acuity at presentation ranged from 20/40 to counting fingers. At the time of VPT diagnosis, intermediate uveitis was active in all eyes. The mean VPT thickness was 3.06 ± 0.86 mm. Local treatment to the VPT was provide in 22 eyes (61.1%) and no local treatment to the VPT in 14 eyes (38.9%). After the VPT was detected, systemic or local treatment for the inflammation was initiated and on follow-up FAs 94.4% of the eyes showed resolution of the vascular leakage. During follow-up of 35.8 months, the 22 VPTs treated locally had a reduction in the tumor thickness to 1.25 mm, whereas the 14 VPTs untreated remained stable (final mean tumor thickness 2.65 mm). CONCLUSION: The presence of active intermediate uveitis accompanied by VPTs suggests the need for an aggressive uveitis treatment.
PURPOSE: To describe patients with intermediate uveitis complicated by vasoproliferative tumors (VPTs). METHODS: Data were collected at seven Uveitis/Ocular Oncology centers on demographic, ophthalmic findings at baseline and at follow-up, and on imaging. The therapeutic intervention, final visual acuity, and duration of follow-up were recorded. RESULTS: A total of 36 eyes from 34 patients (12 men, 22 women; mean age 35.3 ± 14.2 years) were included in this study. Visual acuity at presentation ranged from 20/40 to counting fingers. At the time of VPT diagnosis, intermediate uveitis was active in all eyes. The mean VPT thickness was 3.06 ± 0.86 mm. Local treatment to the VPT was provide in 22 eyes (61.1%) and no local treatment to the VPT in 14 eyes (38.9%). After the VPT was detected, systemic or local treatment for the inflammation was initiated and on follow-up FAs 94.4% of the eyes showed resolution of the vascular leakage. During follow-up of 35.8 months, the 22 VPTs treated locally had a reduction in the tumor thickness to 1.25 mm, whereas the 14 VPTs untreated remained stable (final mean tumor thickness 2.65 mm). CONCLUSION: The presence of active intermediate uveitis accompanied by VPTs suggests the need for an aggressive uveitis treatment.
Authors: Jose Garcia-Arumi; Laura N Distefano; Alex Fonollosa; Claudia Quijano; Borja Corcostegui Journal: Ophthalmic Res Date: 2015-06-06 Impact factor: 2.892
Authors: Aryeh L Pollack; H Richard McDonald; Robert N Johnson; Everett Ai; Alexander R Irvine; J Michael Lahey; Hilel Lewis; Alvaro Rodriguez; Edwin H Ryan; Carol L Shields Journal: Retina Date: 2002-12 Impact factor: 4.256
Authors: Asterios Diafas; Victoria Toumanidou; Ioannis Kassos; Maria Samouilidou; Anna Dastiridou; Nikolaos Ziakas; Sofia Androudi Journal: Int Ophthalmol Date: 2021-06-25 Impact factor: 2.031